2026年1月初, 狼人治疗公司董事Luke Evnin出售了价值245K美元(290K美元)的股份, Werewolf Therapeutics director Luke Evnin sold shares worth $245K–$290K in late December–early January 2026, reducing his stake by 0.75%–1.37%.

狼人治疗 (HOWL) 总监卢克·埃文宁在2026年12月15日至1月2日期间出售了383,183至443,137股,产生了245,500至289,827美元的收益,最近的出售是在1月2日以每股0.63美元的价格进行的. Werewolf Therapeutics (HOWL) Director Luke Evnin sold between 383,183 and 443,137 shares from December 15 to January 2, 2026, generating $245,500 to $289,827, with the most recent sale on January 2nd at $0.63 per share. 他现在拥有大约247万股, 将股份减少0.75%到1.37%。 He now owns approximately 2.47 million shares, a 0.75% to 1.37% reduction in his stake. 该公司报告的季度损失为每股0.36美元,略高于预期,股票交易额约为64美元,市场上限为3 130万美元。 The company reported a quarterly loss of $0.36 per share, slightly better than expected, and the stock traded around $0.64 with a market cap of $31.3 million. 机构投资者持有64.84%的股份,分析师保持混合评级,“坚持”一致,价格目标为3.75美元。 Institutional investors hold 64.84% of shares, and analysts maintain a mixed rating with a consensus "Hold" and a $3.75 price target.